Assessment of the morphological and functional effects of the anti-angiogenic agent SU11657 on 9L gliosarcoma vasculature using dynamic susceptibility contrast MRI

Magnetic Resonance in Medicine

Volumn 57, Issue 4, 2007, Pages 680-687

  Quarles, C C ^a   Schmainda, Kathleen M ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Anti angiogenic therapy; Brain tumor; DSC MRI; Tumor perfusion

Indexed keywords

BRAIN; HEMODYNAMICS; MAGNETIC RESONANCE IMAGING; MAGNETIC SUSCEPTIBILITY; TUMORS;

ANTI-ANGIOGENIC THERAPY; BRAIN TUMORS; DSC MRI; DYNAMIC SUSCEPTIBILITY CONTRAST; DYNAMIC SUSCEPTIBILITY CONTRAST MRIS; FUNCTIONAL CHANGES; MICRO-VASCULATURE; TUMOR PERFUSION;

BLOOD;

ANGIOGENESIS INHIBITOR; SU 11657; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD FLOW; BLOOD VESSEL DIAMETER; BLOOD VOLUME; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SENSITIVITY; DYNAMICS; ELECTRON SPIN RESONANCE; FUNCTIONAL ASSESSMENT; GLIOSARCOMA; INTESTINE TRANSIT TIME; MALE; MORPHOLOGY; NON INVASIVE PROCEDURE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; TUMOR VASCULARIZATION;

EID: 34248364723     PISSN: 07403194     EISSN: 15222594     Source Type: Journal    
DOI: 10.1002/mrm.21193     Document Type: Article

References (40)

1. Abrams TJ, Murray LJ, Pesenti E, Holway VW, Colombo T, Lee LB, Cherrington JM, Pryer NK. Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with "standard of care" therapeutic agents for the treatment of breast cancer. Mol Cancer Ther 2003;2:1011-1021.
2. Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong AT, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington JM. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000; 60:4152-4160.
3. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9: 685-693.
4. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vasuclar endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-3736.
5. Ansiaux R, Baudelet C, Jordan B, Beghein N, Feron O, Gregoire V, Gallez B. Changes in the tumor microenvironment early after treatment with the anti-angiogenic agent thalidomide. In: Proceedings of the 11th Annual Meeting of the ISMRM, Kyoto, Japan, 2004. p 2004.
6. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989.
7. Weber MA, Zoubaa S, Schlieter M, Juttler E, Huttner HB, Geletneky K, Ittrich C, Lichy MP, Kroll A, Debus J, Giesel FL, Hartmann M, Essig M. Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology 2006;66:1899-1906.
8. Wolf RL, Wang J, Wang S, Melhem ER, O'Rourke DM, Judy KD, Detre JA. Grading of CNS neoplasms using continuous arterial spin labeled perfusion MR imaging at 3 Tesla. J Magn Reson Imaging 2005;22:475-482.
9. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, Larsson HB, Lee TY, Mayr NA, Parker GJ, Port RE, Taylor J, Weisskoff RM. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999;10:223-232.
10. Kelcz F, Furman-Haran E, Grobgeld D, Degani H. Clinical testing of high-spatial-resolution parametric contrast-enhanced MR imaging of the breast. AJR Am J Roentgenol 2002;179:1485-1492.
11. Brasch R, Turetschek K. MRI characterization of tumors and grading angiogenesis using macromolecular contrast media: status report. Eur J Radiol 2000;34:148-155.
12. Morakkabati N, Leutner CC, Schmiedel A, Schild HH, Kuhl CK. Breast MR imaging during or soon after radiation therapy. Radiology 2003; 229:893-901.
13. Ostergaard L, Weisskoff RM, Chesler DA, Gyldensted C, Rosen BR. High resolution measurement of cerebral blood flow using intravascular tracer bolus passages. Part I: Mathematical approach and statistical analysis. Magn Reson Med 1996;36:715-725.
14. Aronen HJ, Gazit IE, Louis DN, Buchbinder BR, Pardo FS, Weisskoff RM, Harsh GR, Cosgrove GR, Halpern EF, Hochberg FH. Cerebral blood volume maps of gliomas: comparison with tumor grade and histologic findings. Radiology 1994;191:41-51.
15. Donahue KM, Krouwer HG, Rand SD, Pathak AP, Marszalkowski CS, Censky SC, Prost RW. Utility of simultaneously acquired gradient-echo and spin-echo cerebral blood volume and morphology maps in brain tumor patients. Magn Reson Med 2000;43:845-853.
16. Sugahara T, Korogi Y, Kochi M, Ushio Y, Takahashi M. Perfusion-sensitive MR imaging of gliomas: comparison between gradient-echo and spin-echo echo-planar imaging techniques. AJNR Am J Neuroradiol 2001;22:1306-1315.
17. Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging-prediction of patient clinical response. Radiology 2006;238:658-667.
18. Dennie J, Mandeville JB, Boxerman JL, Packard SD, Rosen BR, Weisskoff RM. NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 1998;40:793-799.
19. Tropes I, Grimault S, Vaeth A, Grillon E, Julien C, Payen J-F, Lamalle L, Decorps M. Vessel size imaging. Magn Reson Med 2001;45:397-408.
20. Jain RK. Determinants of tumor blood flow: a review. Cancer Res 1988;48:2641-2658.
21. Gillies RJ, Schornack PA, Secomb TW, Raghunand N. Causes and effects of heterogeneous perfusion in tumors. Neoplasia 1999;1:197-207.
22. Vajkoczy P, Menger MD. Vascular microenvironment in gliomas. Cancer Treat Res 2004;117:249-262.
23. Gee MS, Saunders HM, Lee JC, Sanzo JF, Jenkins WT, Evans SM, Trinchieri G, Sehgal CM, Feldman MD, Lee WM. Doppler ultrasound imaging detects changes in tumor perfusion during antivascular therapy associated with vascular anatomic alterations. Cancer Res 2001;61: 2974-2982.
24. Ostergaard L, Sorensen AG, Chesler DA, Weisskoff RM, Koroshetz WJ, Wu O, Gyldensted C, Rosen BR. Combined diffusion-weighted and perfusion-weighted flow heterogeneity magnetic resonance imaging in acute stroke. Stroke 2000;31:1097-1103.
25. Boxerman JL, Hamberg LM, Rosen BR, Weisskoff RM. MR contrast due to intravascular magnetic susceptibility perturbations. Magn Reson Med 1995;34:555-566.
26. Majumdar S, Zoghbi S, Gore JC. The influence of pulse sequence on the relaxation effects of superparamagnetic iron oxide contrast agents. Magn Reson Med 1989;10:289-301.
27. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbunthemg J, Blake RA, Sun C, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of pharmacokinetic/ pharmacodynamic relationship. Clin Cancer Res 2003;9:327-337.
28. Sohal J, Phan VT, Chan PV, Davis EM, Patel B, Kelly LM, Abrams TJ, O'Farrell AM, Gilliland DG, Le Beau MM, Kogan SC. A model of APL with FLT3 mutation is responsive to retinole acid and a receptor tyrosine kinase inhibitor, SU11657. Blood 2003;101:3188-3197.
29. Kottaridis PD, Gale RE, Linch DC. Flt3 mutations and leukaemia. Br J Haematol 2003;122:523-538.
30. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, Xiao S, Singer S, Fletcher CD, Fletcher JA. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000;156: 791-795.
31. Backman U, Christofferson R. The selective class III/V receptor tyrosine kinase inhibitor SU11657 inhibits tumor growth and angiogenesis in experimental neuroblastomas grown in mice. Pediatr Res 2005;57(5 Pt 1):690-695.
32. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Grone HJ, Debus J, Lipson KE, Abdollahi A. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005;65:3643-3655.
33. Mandeville JB, Moore J, Chesler DA, Garrido L, Weissleder R, Weisskoff RM. Dynamic liver imaging with iron oxide agents: effects of size and biodistribution on contrast. Magn Reson Med 1997;37:885-890.
34. Badruddoja MA, Krouwer HG, Rand SD, Rebro KJ, Pathak AP, Schmainda KM. Antiangiogenic effects of dexamethasone in 9L gliosarcoma assessed by MRI cerebral blood volume maps. Neuro-Oncology 2003;5:235-243.
35. Ostergaard L, Chesler DA, Weisskoff RM, Sorensen AG, Rosen BR. Modeling cerebral blood flow and flow heterogeneity from magnetic resonance residue data. J Cereb Blood Flow Metab 1999;19:690-699.
36. O'Farrel IAM, Abrams TJ, Yuen HA, Ngai T, Louie SG, Yee KWH, Wong LM, Hong WM, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003;101: 3597-3605.
37. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, Wang B, Bukofzer GT, Wang YC, Stavropoulos JA, Hartandi K, Niquette AL, Soni N, Johnson EF, McCall JO, Bouska JJ, Luo Y, Donawho CK, Dai Y, Marcotte PA, Glaser KB, Michaelides MR, Davidsen SK. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 2006;5: 995-1006.
38. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60: 1878-1886.
39. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 2002;62:1702-1706.
40. Geng L, Donnelly E, McMahon G, Lin PC, Sierra-Rivera E, Oshinka H, Hallahan DE. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;61:2413-2419.